BeOne Medicines (NASDAQ:ONC) Price Target Raised to $396.00 at Citizens Jmp

BeOne Medicines (NASDAQ:ONC) had its price target hoisted by Citizens Jmp from $348.00 to $396.00 in a research note published on Friday,Benzinga reports. They currently have a market outperform rating on the stock.

Other analysts also recently issued research reports about the company. Morgan Stanley boosted their target price on BeOne Medicines from $350.00 to $383.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. Guggenheim increased their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $353.00.

BeOne Medicines Price Performance

ONC traded down $12.39 during trading on Friday, reaching $319.97. The stock had a trading volume of 339,919 shares, compared to its average volume of 226,906. The business has a 50-day moving average of $326.91 and a 200-day moving average of $287.77. BeOne Medicines has a one year low of $170.99 and a one year high of $355.30. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95. The stock has a market cap of $35.09 billion, a PE ratio of 627.39 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.36. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BeOne Medicines had a return on equity of 5.76% and a net margin of 1.38%. As a group, equities research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 11,013 shares of the business’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $300.45, for a total value of $3,308,855.85. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $337.00, for a total value of $898,105.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 157,074 shares of company stock valued at $49,396,898. Company insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ONC. Anchor Investment Management LLC bought a new position in BeOne Medicines during the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd bought a new position in shares of BeOne Medicines during the second quarter valued at $28,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at $35,000. Farther Finance Advisors LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter worth about $39,000. Finally, Signaturefd LLC bought a new position in BeOne Medicines in the 2nd quarter worth about $49,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.